Compare Marsh & McLennan Companies, Inc. (MRSH) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Sanofi SA — how do they compare? Marsh & McLennan Companies, Inc. trades at $176.89 (market cap $86.15B), while Sanofi SA trades at $43.12 (market cap $104.06B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.61%). Which is the better fit depends on your goals.
| MRSH | SNY | |
|---|---|---|
Market Cap | $86.15B | $104.06B |
Sector | Financials | Health |
52-Week High | $207.02 | $52.34 |
52-Week Low | $157.32 | $41.33 |
Enterprise Value | $106.83B | $124.09B |
Dividend Yield | 2.19% | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh & McLennan (MRSH) trades at $180.52, down 2.81% on the day, with a bullish technical signal despite recent weakness. The stock shows strong fundamentals, including consistent earnings beats, a 14.24% net income margin, and robust cash flow. Recent news highlights growth in healthcare consulting and cyber risk services, supporting revenue expansion.
Outlook remains positive with a consensus price target of $208.63, offering 15% upside. Risks include economic sensitivity and debt levels, but analyst sentiment leans bullish with 30% buy ratings. The stock presents a growth opportunity in professional services, backed by solid financials and strategic initiatives.
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
